Lower urinary tract symptoms and COVID-19


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The data presented in the review showed that the coronavirus affects not only the lungs, but also the organs of the urinary system. The new virus causes a mosaic, multi-organ disease with severe consequences after the egg and has a wide organotropism. The role of SARS-CoV-2 in the development of lower urinary tract symptoms (LUTs), which are manifested by frequent, imperative urges, dysuria, nocturia, is not entirely clear. It is assumed that biologically active substances, the activation of which is caused by a virus, play a certain role in the development of SNMP, namely the expression of angiotensin converting enzyme 2 (ACE2), cytokines, activation of tolllike receptor 4 (TLR4), etc. An increase in cytokines that are released into the urine and / or expressed in the bladder and the presence of SNMP in patients with coronavirus infection have been called de novo urinary symptoms or COVID-19 associated cystitis (CAC) in the literature. Urinary symptoms de novo or associated cystitis COVID-19 (CAC) develops against the background of a complete lack of data for the presence of a bacterial pathogen in the urine. Despite the unusual manifestation of coronavirus infection, similar mechanisms of damage to urothelial cells in viral and bacterial infections give us the right to think about the use of pathogenetically justified prevention of the development of an inflammatory reaction in the urinary tract, as well as short-and longterm consequences of this disease. For this purpose, it is necessary to recommend drugs that have a multifactorial effect: diuretic, anti-adhesive, anti-inflammatory and regulate the local immunity of the bladder mucosa. We assume that against this background, we can expect a decrease in the number of complications from the organs of the urinary system, and more successful rehabilitation of patients with coronavirus infection and in the post-ovarian period. Final conclusions and recommendations will be available after well-planned clinical trials have been conducted.

Full Text

Restricted Access

About the authors

A. N Bernikov

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Email: bernikov@mac.com
Ph.D., associated professor at the Department of Urology

A. A Kupriyanov

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov; State Budgetary Institution «Research Institute of Health Organization and Medical Management of the Moscow Department of Health»

Email: dr.kupriyanov@mail.ru
Ph.D., assistant at the Department of Urology

R. V Stroganov

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov; State Budgetary Institution «Research Institute of Health Organization and Medical Management of the Moscow Department of Health»

Ph.D., senior laboratory assistant at the Department of Urology

O. A Arefieva

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov; State Budgetary Institution «Research Institute of Health Organization and Medical Management of the Moscow Department of Health»

Ph.D., senior laboratory assistant at the Department of Urology

L. A Khodyreva

State Budgetary Institution «Research Institute of Health Organization and Medical Management of the Moscow Department of Health»

Email: khodyreva60@mail.ru
Ph.D., MD, professor

A. V Zaitsev

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Email: zaitcevandrew@mail.ru
Ph.D., MD, professor at the Department of Urology

References

  1. Elsayed Desouky. SARS-CoV-2 tropism: what urologists need to know. African Journal of Urology. 2021;27:23 https://doi.org/10.1186/s12301-021-00126-0
  2. Melika Lotfi, Nima Rezaei. SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences. J. Med. Virol. 2020. doi: 10.1002/jmv.26123
  3. Малхасян В.А., Касян Г.Р., Ходырева Л.А., Колонтарев К.Б., Говоров А.В., Васильев А.О., Пушкарь Д.Ю. Оказание стационарной помощи пациентам урологического профиля в условиях пандемии коронаровирусной инфекции COVID-19. Экспериментальная и клиническая урология. 2020;1:4-11. doi: 10.29188/2222-8543-2020-12-1-4-11
  4. Puelles V., Lftgehetmann M., Lindenmeyer M., Sperhake J. et al. Multiorgan and renal tropism of SARS-CoV-2. N. Engl J. Med. 2020;383(6):590-592.
  5. Amir H. Kashi, Jean De la Rosette, Erfan Amini, Hamidreza Abdi, Morteza Fallah-Karkan, Maryam Vaezjalali. Urinary Viral Shedding of COVID-19 and its Clinical Associations: A Systematic Review and Meta-analysis of Observational Studies Urol J. 2020;17(5):433-441. doi: 10.22037/uj.v16i7.6248.
  6. Charles Feldman, Ronald Anderson The role of co-infections and secondary infections in patients with COVID-19. Pneumonia (Nathan). 2021;13(1):5. doi: 10.1186/s41479-021-00083-w.
  7. Nori P., Cowman K., Chen V., Bartash R., Szymczak W., Madaline T. et al. Bacterial and fungal co-infections in COVID-19 patients hospitalized during the New York City Pandemic Surge. Infect Control Hosp Epidemiol. 2020. Doi: https://doi.org/10.1017/ice.2020.368
  8. Christophe Masset, Simon Ville, Franck Halary, Benjamin Gaborit, Celine Bressolette-Bodin, Clement Deltombe,Amaury Dujardin, Lola Jacquemont, Sabine Lebot, Delphine Kervella, Lucille Figueres, Diego Cantarovich, Magali Giral, Maryvonne Hourmant, Gilles Blancho, Claire Garandeau, Aurelie Meurette, Jacques Dantal Resurgence of BK virus following Covid-19 in kidney transplant recipients, Transpl. Infect. Dis. 2021;23:e13456/ doi: 10.1111/tid.13465.
  9. Fry C.H., Vahabi B. The Role ofthe Mucosa in Normal and Abnormal Bladder function. Basic & clinical pharmacology & toxicology. 2016;119(Suppl. 3):57-62. doi: 10.1111/bcpt.12626.
  10. Breyer B.N., Van den Eeden S.K., Horberg MA., Eisenberg M.L., Deng D.Y., Smith J.F., et al. HIV status is an independent risk factor for reporting lower urinary tract symptoms. J. Urol 2011;185(5):1710-15. PubMed PMID: 21420120. Pubmed Central PMCID: PMC3565615. Epub 2011/03/2eng
  11. Castro N.M., Rodrigues W., Jr., Freitas D.M., Muniz A., Oliveira P., Carvalho E.M. Urinary symptoms associated with human T-cell lymphotropic virus type I. infection: evidence of urinary manifestations in large group of HTLV-I carriers. Urology. 2007;69(5):813-818. PubMed PMID: 17482910. Epub 2007/05/08. eng. [PubMed] [Google Scholar
  12. Song H., Seddighzadeh B., Cooperberg M., Huang F. Expression of ACE2, the SARS-CoV-2 receptor, and TMPRSS2 in prostate epithelial cells. Eur Urol. 2020;78(2):296-298. https://doi.org/10.1016Zj.eururo.2020.04.065
  13. Pan F., Xiao X., Guo J. et al. No evidence of SARS-CoV-2 in semen of males recovering from COVID-19. Fertil Steril. 2020;113(6):1135-1139. https://doi.org/10.1016/j.fertnstert.2020.04.024
  14. Mumm J., Osterman A., Ruzicka M. et al. (2020) Urinary frequency as a possibly overlooked symptom in COVID-19 patients: does SARS-CoV-2 cause viral cystitis? Eur Urol 78(4):624-628. https://doi.org/10.1016/j.eururo.2020.05.013
  15. Ines Ambite, Daniel Butler, Murphy Lam Yim Wan, Therese Rosenblad’, Thi Hien Tran, Sing Ming Chao и Catharina Svanborg Molecular determinants of disease severity in urinary tract infection Nat Rev Urol. 2021;18(8):468-486. doi: 10.1038/s41585-021-00477-x. https://doi.org/10.1038/s41585-021-00477-x
  16. O’Neill L.A., Golenbock D., Bowie A.G. The history of Toll-like receptors - redefining innate immunity. Nat. Rev. Immunol. 2013;13:453-460.
  17. Миркин Я.Б., Карапетян А.В. Интерстициальный цистит: патогенез, диагностика и лечение (часть 2). 2018;2:118-122
  18. Амирова Ж.С., Балан В.Е., Ковалёва Л.А., Ермакова Е.И. Новое в диагностике гиперактивного мочевого пузыря. Российский вестник акушера-гинеколога. 2015;15(4):18-22. doi: 10.17116/rosakush201515418-22
  19. Laura E. Lamb, Nivedita Dhar, Ryan Timar, Melissa Wills et al. COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC) Med Hypotheses. 2020;145:110375. Doi: 10.1016/j. mehy.2020.110375.
  20. Nivedita Dhar, Sorabh Dhar, Ryan Timar, Steven Lucas, Laura E. Lamb, Michael B. Chancellord. De Novo Urinary Symptoms Associated With COVID-19: COVID-19-Associated Cystitis J. Clin Med Res. 2020;12(10):681-682. doi: 10.14740/jocmr4294.
  21. Ramin Haghighi, Seyed Ahmad Hashemi, Ali Abaszade Ganji, Ashkan Haghighi, Samaneh Mollazadeh. Unexpected urological presentation of COVID-19 in a 41-year-old female: A case report. Clin Case Rep. 2021;9(3):1691-1693. doi: 10.1002/ccr3.3882.
  22. Sun J., Zhu A., Li H., Zheng K., Zhuang Z., Chen Z., et al. Isolation of Infectious SARS-CoV-2 from Urine of a COVID-19 Patient. Emerg Microbes Infect 2020;28:1-8. doi: 10.1080/22221751.2020.1760144.
  23. Cheng Y., Luo R., Wang K., Zhang M., Wang Z., Dong L., et al. Kidney impairment is associated with inhospital death of COVID-19 patients. Kidney Int. 2020;97(5):829-838. doi: 10.1016/j.kint.2020.03.005.
  24. Yeliz Kaya, Coskun Kaya, Tugba Kartal, Tugba Tahta, Tokgoz V. Yavuz. Could LUTS be Early Symptoms of COVID-19 Int J. Clin Pract. 2021;75(3):e13850. doi: 10.1111/ijcp.13850. Epub 2020 Dec 4. doi: 10.1111/IJCP.13850.
  25. Osman Can, Mustafa Erkog, Murat Ozer, Musab Umeyir Karakanli, Alper Otunctemur The effect of COVID-19 on lower urinary tract symptoms in elderly men. Int J. Clin Pract. 2021 ;00:e14110. https://doi.org/10.1111/ijcp.14110 doi: 10.1111/ijcp.14110
  26. Kranjcec B., Papes D., Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J. Urol. 2014;32:79-84. https://dx.doi.org/10.1007/s00345-013-1091-6
  27. Stacy M. Lenger, Megan S. Bradley, Debbie A Thomas, Marnie H. Bertolet, Jerry L. Lowder, Siobhan Sutcliffe. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and metaanalysis Affiliations expand. PMID: 32497610 PMCID: PMC7395894. doi: 10.1016/j.ajog.2020.05.048.
  28. Franssen M., Cook J., Robinson J., Williams N., Glogowska M., Yang Y. et al. D-MannosE to prevent recurrent urinary tract InfecTions (MERIT): protocol for a randomised controlled trial. BMJ Open. 2021;11(1):e037128. https://dx.doi.org/10.1136/bmjopen-2020-037128
  29. Gan J., Dou Y., Li Y., Wang Z., Wang L., Liu S., et al. Producing antiinflammatory macrophages by nanoparticle-triggered clustering of mannose receptors. Biomaterials 2018;178:95-108. Doi: 10.1016/j. biomaterials.2018.06.015.
  30. Jepson R.G., Mihaljevic L., Graig J. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2004;(1): CD001321. doi: 10.1002/14651858.CD001321.
  31. Sobota A.E. Inhibition of bacterial adherence by cranberry juice: potential use for the treatment of urinary tract infections. J. Urol. 1984;131(5):1013-1016. https://dx.doi.org/10.1016/S0022-5347(17)50751-X
  32. Kiyah J. Duffey, Lisa A. Sutherlandb. Adult consumers of cranberry juice cocktail have lower C-reactive protein levels compared with nonconsumers. Nutr Res. 2015;35(2):118-126. doi: 10.1016/j.nutres.2014.11.005. 6
  33. Sujana K., Sai Tejaswini K., SriLakshmi S. Cranberry fruit: An update review. International Journal of Herbal Medicine. 2016;4(3):5-8.
  34. Hertting O., Holm A., Luthje P., Brauner H., Dyrdak R., Jonasson A.F. et al. Vitamin D induction of the human antimicrobial peptide cathelicidin in the urinary bladder. PLoS One. 2010;5:e15580. https://dx.doi.org/10.1371/journal.pone.0015580

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies